Rocket Pharmaceuticals remains in a high-risk, pre-revenue phase, with its valuation heavily dependent on the successful clinical execution of its gene therapy pipeline. The company faces significant financial pressure as quarterly operating losses consistentl...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 10, 2026 | $1.08+25.6% vs $0.86 | — vs $18M |
Q2 2026 May 7, 2026 | -$0.42-2.4% vs -$0.41 | — vs $4M |
Q1 2026 Feb 26, 2026 | -$0.38+9.5% vs -$0.42 | — vs $277,778 |
Q4 2025 Nov 6, 2025 | -$0.45+6.3% vs -$0.48 | — vs $312,500 |
Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.
As the Federal Reserve prepares to move on rates and oil prices surge past $105, Wednesday's top analyst calls reveal which travel giants, homebuilders, and financial stocks Wall Street is quietly repositioning around before the dust settles.
Rocket Pharmaceuticals, Inc. (RCKT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Rocket Pharmaceuticals, Inc. (RCKT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Benchmark RCKT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Rocket Pharmaceuticals, Inc. (RCKT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.35 | $365.8M | -1.67 | — | — | -60.27% | — | |
| $59.03 | $5.69B | -9.12 | -89.97% | -3368.72% | -24.39% | — | |
| $2.92 | $448.11M | -1.62 | 25.39% | -157.32% | -196.63% | — | |
| $25.93 | $2.67B | -32.01 | 120.01% | -54.75% | -7.7% | — | |
| $12.69 | $1.42B | -3.33 | 16.92% | -672.16% | -57.79% | — | |
| $0.07 | $30.66M | -0.17 | -31.57% | -356.89% | — | — |
Rocket Pharmaceuticals, Inc. (RCKT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Rocket Pharmaceuticals, Inc. (RCKT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 10, 2026·SEC
Aug 3, 2026·SEC
Jun 30, 2026·SEC
Get notified when RCKT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Rocket Pharmaceuticals, Inc. (RCKT) stock FAQ — growth, dividends, profitability & financials explained
Rocket Pharmaceuticals, Inc. (RCKT) reported a net loss of $17.3M for fiscal year 2025.
Rocket Pharmaceuticals, Inc. (RCKT) has a return on equity (ROE) of -60.3%. Negative ROE indicates the company is unprofitable.
Rocket Pharmaceuticals, Inc. (RCKT) had negative free cash flow of $170.4M in fiscal year 2025, likely due to heavy capital investments.
